- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Concord Biotech reported strong Q1 FY27 revenues of ₹257 Cr, up 26% YoY, with API segment growing 42% and exports surging 46%. Gross margins improved to 78.9%, and EBITDA reached ₹82 Cr (32% margin, up 190 bps YoY). Management is confident in sustaining momentum, targeting ₹3,000 Cr revenue in 5-6...
Concord Biotech reported strong Q1FY27 financial results: Revenue jumped 26% to Rs 257.5 Cr, EBITDA grew 34% to Rs 82.4 Cr, and PAT increased 31% to Rs 57.7 Cr. Exports surged 46% YoY, driving broad-based growth across products and geographies. The company secured USFDA approvals for Mycophenolate Mofetil and Tofacitinib...